Try our Advanced Search for more refined results

R&D Impact May Be Key In Scrutiny Of Pfizer Oncology Deal

By Chelsea Naso (August 23, 2016, 6:13 PM EDT) -- U.S. pharmaceutical giant Pfizer's planned $14 billion acquisition of oncology biotech Medivation could sail through an antitrust review given their minimal product overlaps, unless regulators opt to heighten their focus on the deal's potential impact on research and development within the cancer treatment space, experts say....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Law Firms

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!